Yang, S.-y.; Ngo, L.T.; Lee, S.; Yun, H.-y.; Bui, T.T.; Kim, D.-H.; Chae, J.-w.; Park, S.
Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Pharmaceuticals 2025, 18, 748.
https://doi.org/10.3390/ph18050748
AMA Style
Yang S-y, Ngo LT, Lee S, Yun H-y, Bui TT, Kim D-H, Chae J-w, Park S.
Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Pharmaceuticals. 2025; 18(5):748.
https://doi.org/10.3390/ph18050748
Chicago/Turabian Style
Yang, Sung-yoon, Lien Thi Ngo, Soyoung Lee, Hwi-yeol Yun, Tham Thi Bui, Dong-Hyeon Kim, Jung-woo Chae, and Sojung Park.
2025. "Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor" Pharmaceuticals 18, no. 5: 748.
https://doi.org/10.3390/ph18050748
APA Style
Yang, S.-y., Ngo, L. T., Lee, S., Yun, H.-y., Bui, T. T., Kim, D.-H., Chae, J.-w., & Park, S.
(2025). Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Pharmaceuticals, 18(5), 748.
https://doi.org/10.3390/ph18050748